Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Enclomiphene and Modafinil Interaction: Avoid | Peptide Database

Compound Profiles Enclomiphene Selective Estrogen Receptor Modulator | Testosterone & Fertility Support Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Modafinil

Eugeroic | Wakefulness & Cognitive Enhancement

The exact mechanism of action of modafinil is not fully understood, which distinguishes it from most prescription stimulants. The primary mechanism appears to involve inhibition of the dopamine transporter (DAT), leading to increased extracellular dopamine concentrations in the nucleus accumbens and cortical regions.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Enclomiphene with Modafinil?

Combining Enclomiphene with Modafinil is not recommended. Both Enclomiphene and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Modafinil safe together?

This combination carries significant risk. Both Enclomiphene and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Modafinil?

Both Enclomiphene and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Modafinil?

Enclomiphene has a half-life of ~10 hours and Modafinil has a half-life of ~12-15 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment. Supports cartilage maintenance and joint function. Supports bone and connective tissue healing. Increased Ki-67 expression with suppressed apoptosis in young and aged cells. Enhances collagen synthesis in connective tissue. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

Source: peptide-db.com ↗

Community Research

Join others researching Superdrol — share findings, ask questions, and learn from real experiences Superdrol (methyldrostanolone, also known as methasterone) is a synthetic oral anabolic-androgenic steroid derived from drostanolone (Masteron) with the addition of a 17-alpha-methyl group for oral bioavailability. It is widely regarded as one of the most potent oral anabolic steroids ever produced, delivering dramatic strength and lean mass gains in very short timeframes. Superdrol was originally marketed in the United States as a "prohormone" dietary supplement beginning in 2005 by Designer Supplements, exploiting a regulatory loophole since it was not explicitly listed as a controlled substance at the time. It was pulled from the market and subsequently classified as a Schedule III controlled substance under the Designer Anabolic Steroid Control Act of 2014. Despite its remarkable anabolic potency, Superdrol carries an extreme hepatotoxicity profile that distinguishes it from virtually all other commonly used oral steroids. Cases of severe cholestatic jaundice, liver failure, and hospitalizations have been reported even at moderate doses and short cycle lengths. It does not aromatize to estrogen, which means it does not cause water retention or gynecomastia, but this also means it provides no estrogenic support for joints, mood, or libido when used without a testosterone base. Superdrol is strictly an advanced-only compound and is not suitable for beginners under any circumstances. Superdrol exerts its effects through high-affinity binding to the intracellular androgen receptor (AR), stimulating androgen-responsive gene transcription that promotes nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle. As a DHT derivative, it cannot be aromatized by the CYP19 aromatase enzyme, so it produces no estrogenic metabolites. This accounts for the characteristic dry, hard appearance it produces without subcutaneous water retention. The 2-alpha-methyl group enhances its anabolic potency relative to its parent compound drostanolone, giving it an anabolic-to-androgenic ratio that significantly favors muscle-building effects over androgenic side effects in target tissues. The 17-alpha-methyl group allows it to survive first-pass hepatic metabolism, but this same modification is responsible for its severe hepatotoxicity. Superdrol is metabolized primarily by the liver, placing enormous stress on hepatic conjugation and bile transport pathways. It has been shown to cause dose-dependent cholestasis by disrupting bile salt export pump (BSEP) function, leading to intrahepatic bile acid accumulation. This mechanism underlies the cholestatic jaundice and hepatocellular injury that are disproportionately common with this compound compared to other 17-alpha-alkylated steroids.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

PNC-27 is currently in preclinical research stages. All dosing data comes from in vitro and animal model studies. No human dosing protocols have been approved. The peptide has shown tumor eradication in nude mice xenograft models. Research protocol Variable by study Research protocols IP or direct tumor injection (research)

Source: peptide-db.com ↗
Potential benefits

What are the cardiovascular benefits of B7-33 compared to other compounds?

B7-33 reduces myocardial fibrosis, enhances vasodilation through nitric oxide pathway, and demonstrates cardioprotective effects in heart failure models. These anti-fibrotic and vasoprotective properties position it for potential use in cardiac remodeling, though all current data is preclinical.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →